Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring

Abstract

Background Direct oral anticoagulants (DOACs) are increasingly replacing vitamin K antagonists (VKA) for clinical indications requiring long-term oral anticoagulation. In contrast to VKA, treatment with DOAC including dabigatran—the only direct thrombin inhibitor amongst them—does not require therapeutic drug monitoring. However, in case of treatment complications (e.g., major haemorrhage) and conditions requiring urgent surgery or thrombolytic therapy, information about actual DOAC plasma levels is needed to guide treatment decisions. Due to short reagent stability, limited accuracy at low dabigatran levels and high heparin sensitivity, the applicability of the widely used Hemoclot thrombin inhibitor (HTI) coagulation assay is limited in the emergency setting.

Methods Dabigatran concentrations of 288 citrated plasma samples taken from 48 dabigatran-treated patients with drug concentrations of up to 300 ng/mL were measured with the chromogenic anti-IIa Biophen direct thrombin inhibitor (BDTI) assay and results compared with HTI using ultra performance liquid chromatography—tandem mass spectrometry as the reference method for measuring dabigatran plasma concentrations.

Results BDTI results showed a very strong correlation with dabigatran concentrations (r = 0.965, p < 0.0001) as well as a low intra- and inter-assay variation of <5%. Compared with HTI, BDTI provides an improved on-board reagent stability of 72 hours, rapid turnaround times comparable to routine coagulation assays, high accuracy at low drug levels and reduced heparin sensitivity.

Conclusion The BDTI is an ideal coagulation assay for the around-the-clock determination of dabigatran plasma levels in clinical routine including emergency situations.

Keywords

oral anticoagulants - clinical trials - dabigatran - NOAC - DOAC

• References

• 1 Connolly SJ, Ezekowitz MD, Yusuf S. , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
• 2 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
• 3 Schulman S, Kearon C, Kakkar AK. , et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
• 4 Kirchhof P, Benussi S, Kotecha D. , et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
• 5 Fitzmaurice DA, Accetta G, Haas S. , et al; GARFIELD-AF Investigators. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. Br J Haematol 2016; 174 (04) 610-623
• 6 Heidbuchel H, Verhamme P, Alings M. , et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34 (27) 2094-2106
• 7 Heidbuchel H, Verhamme P, Alings M. , et al; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15 (05) 625-651
• 8 Ebner M, Peter A, Spencer C. , et al. Point-of-care testing of coagulation in patients treated with non-vitamin k antagonist oral anticoagulants. Stroke 2015; 46 (10) 2741-2747
• 9 Artunc F, Muehlbacher T, Baumann D. , et al. Removal of dabigatran is superior by sustained low efficient dialysis (SLED) compared to intermittent hemodialysis. Blood Purif 2015; 39 (04) 331-332
• 10 Baumann D, Haap M, Tsaousidis C. , et al. Vaginal bleeding as symptom of a medical emergency—pitfalls of therapy with new oral anticoagulants - case 5/2014. Dtsch Med Wochenschr 2014; 139 (30) 1539
• 11 Graham DJ, Reichman ME, Wernecke M. , et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016; 176 (11) 1662-1671
• 12 Beyer-Westendorf J, Ebertz F, Förster K. , et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113 (06) 1247-1257
• 13 Hecker J, Marten S, Keller L. , et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2016; 115 (05) 939-949
• 14 Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28 (11) 1354-1373
• 15 Steiner T, Böhm M, Dichgans M. , et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102 (06) 399-412
• 16 Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. Clin Chem Lab Med 2015; 53 (02) 185-197
• 17 Douxfils J, Lessire S, Dincq AS. , et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost 2015; 113 (04) 862-869
• 18 Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107 (05) 985-997
• 19 Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010; 104 (05) 1078-1079
• 20 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23 (02) 138-143
• 21 Amiral J, Dunois C, Amiral C, Seghatchian J. An update on laboratory measurements of dabigatran: smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma. Transfus Apheresis Sci 2016; 54 (03) 428-437
• 22 Hawes EM, Deal AM, Funk-Adcock D. , et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11 (08) 1493-1502
• 23 Chin PK, Wright DF, Patterson DM, Doogue MP, Begg EJ. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol 2014; 78 (03) 599-609
• 24 Kuhn J, Gripp T, Flieder T. , et al. UPLC-MRM mass spectrometry method for measurement of the coagulation inhibitors dabigatran and rivaroxaban in human plasma and its comparison with functional assays. PLoS One 2015; 10 (12) e0145478
• 25 Passing H. , Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983; 21 (11) 709-720
• 26 Evans JD. Straightforward Statistics for the Behavioral Sciences. Pacific Grove, CA: Brooks/Cole Publishing Company; 1996
• 27 Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8 (02) 135-160
• 28 Hollis S. Analysis of method comparison studies. Ann Clin Biochem 1996; 33 (Pt 1): 1-4
• 29 Pernod G, Albaladejo P, Godier A. , et al; Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)—March 2013. Arch Cardiovasc Dis 2013; 106 (6–7): 382-393
• 30 Faraoni D, Levy JH, Albaladejo P, Samama CM. ; Groupe d'Intérêt en Hémostase Périopératoire. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care 2015; 19: 203
• 31 Godier A, Martin AC, Leblanc I. , et al. Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations. Thromb Res 2015; 136 (04) 763-768
• 32 Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report Pradaxa. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000829/WC500110875.pdf . Accessed Feb 20, 2016
• 33 Eikelboom JW, Connolly SJ, Brueckmann M. , et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13) 1206-1214